Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 05

1864P - To what extent do nulliparous, female adolescents and young adults diagnosed with cancer have children after cancer treatment?

Date

21 Oct 2023

Session

Poster session 05

Topics

Cancer in Adolescents and Young Adults (AYA);  Cancer Registries;  Psycho-Oncology;  Survivorship;  Cancer Research

Tumour Site

Presenters

Line Bentsen

Citation

Annals of Oncology (2023) 34 (suppl_2): S1001-S1012. 10.1016/S0923-7534(23)01947-6

Authors

L. Bentsen1, L.B. Colmorn2, H. Pappot1, K.L.T. Macklon2, D. Vassard2

Author affiliations

  • 1 Department Of Oncology, Copenhagen University Hospital, Rigshospitalet, 2100 - Copenhagen/DK
  • 2 Department Of Fertility, Copenhagen University Hospital, Rigshospitalet, 2100 - Copenhagen/DK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1864P

Background

Globally, more than 1.3 mio adolescents and young adults (AYAs) are diagnosed with cancer each year. Long-term survival has increased due to improved cancer therapy; however, a potential side effect is reduced fertility. Despite development in fertility preservation uncertainty regarding future fertility is still of major concern to the AYAs. The aim of this study was to identify to what extent nulliparous, female AYAs with cancer have children after cancer treatment compared to nulliparous female AYAs without cancer.

Methods

This is a national register study based on the Danish National Assisted Reproductive Technology-Couple cohort including female AYAs diagnosed with cancer when aged 18-39 from 1978–2016. According to diagnosis onset, the female AYAs with cancer were randomly age-matched with 60 female AYAs without cancer (comparison group: CG). Study participants were followed until end of study, death, or migration (31/12-2017). Death was incorporated as a competing risk in all analyses. Hazard Ratio (HR) were calculated, comparing the female AYAs with cancer with the CG. HR was adjusted for time of diagnosis, immigration status, marital status, and educational level.

Results

33.3% of AYAs with cancer had at least one child after cancer treatment vs. 40% in the CG. Female AYAs with malignant melanoma had solely a higher HR of having children after cancer treatment compared to the CG. Female AYAs with leukaemia, breast and CNS cancer had the lowest HR of having children after cancer treatment, especially in the age interval 32-39 years. Table: 1864P

N (%) ≥ 1 child after cancer N (%) Adjusted HR (95% CI)*
18-25 y 26-31 y 32-39 y
All 7519 (100) 2505 (33.3) 0.77 (0.72-0.82) 0.65 (0.61-0.69) 0.59 (0.52-0.67)
Gyn cancer 1773 (23.6) 435 (24.5) 0.49 (0.42-0.58) 0.44 (0.38-0.50) 0.39 (0.29-0.52)
Breast cancer 1115 (14.8) 179 (16.1) 0.63 (0.42-0.95) 0.46 (0.37-0.56) 0.35 (0.26-0.48)
Mal melanoma 1960 (26.1) 1071 (54.6) 1.02 (0.93-1.12) 1.03 (0.93-1.13) 1.13 (0.92-1.39)
CNS cancer 303 (4.0) 65 (21.5) 0.70 (0.51-0.97) 0.40 (0.26-0.61) 0.25 (0.06-0.97)
Leukaemia 258 (3.4) 37 (14.3) 0.39 (0.26-0.57) 0.25 (0.09-0.65) 0.41 (0.13-1.26)
Lymphoma 278 (3.7) 78 (28.1) 0.63 (0.47-0.85) 0.48 (0.30-0.75) 0.76 (0.32-1.84)
CG 499,616 199,861 (40.0) 1 1 1

*Adjusted analysis is based on complete case sample, N=6275. Approximately 16% (6275/7519) is excluded in the adjusted analysis due to missing data.

Conclusions

A third of nulliparous, female AYAs with cancer had at least one child after cancer which is lower than for female AYAs without cancer. The HR for having children after cancer decrease with increased age being lowest in female AYAs with leukaemia, breast- and CNS cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.